NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-K for the period ended Sep 30, 2019
Filed with the SEC on Dec 20, 2019 and accepted by EDGAR at Dec 20, 2019, 22:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2018-10-01 to 2019-09-30 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months2018-10-01 to 2019-09-30 | −$5.8m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months2018-10-01 to 2019-09-30 | −$6.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2018-10-01 to 2019-09-30 | −$0.57 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2018-10-01 to 2019-09-30 | −$5.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-10-01 to 2019-09-30 | $58.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-09-30 | $260.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $301.8k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $532.6k | us-gaap:Assets |
| Current liabilities | At period end2019-09-30 | $1.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-09-30 | $1.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | −$1.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-19-026720. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.